Insider Selling: Cue Biopharma (NASDAQ:CUE) Insider Sells $265,664.61 in Stock

Cue Biopharma, Inc. (NASDAQ:CUE) insider Sumita Ray sold 8,829 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $30.09, for a total transaction of $265,664.61. Following the completion of the sale, the insider directly owned 118,545 shares in the company, valued at approximately $3,567,019.05. The trade was a 6.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cue Biopharma Trading Up 2.3%

Shares of CUE opened at $26.28 on Thursday. The stock has a market cap of $110.38 million, a P/E ratio of -0.97 and a beta of 2.47. The company has a 50-day moving average of $29.34 and a two-hundred day moving average of $139.45. Cue Biopharma, Inc. has a 12-month low of $4.97 and a 12-month high of $45.50.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The business had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%.

Institutional Trading of Cue Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Cue Biopharma during the 2nd quarter worth about $722,000. Persistent Asset Partners Ltd acquired a new stake in shares of Cue Biopharma in the second quarter worth approximately $389,000. GC Wealth Management RIA LLC grew its holdings in Cue Biopharma by 35.0% in the fourth quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock valued at $1,415,000 after purchasing an additional 1,200,000 shares during the period. Boothbay Fund Management LLC grew its holdings in Cue Biopharma by 15.3% in the fourth quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock valued at $215,000 after purchasing an additional 93,333 shares during the period. Finally, Stifel Financial Corp increased its position in Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares during the last quarter. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Wall Street Analyst Weigh In

CUE has been the topic of a number of analyst reports. Wall Street Zen cut Cue Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Cue Biopharma in a research report on Thursday, August 13th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.